“Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study” (2019) SKIN The Journal of Cutaneous Medicine, 3, p. S34. doi:10.25251/skin.3.supp.34.